Bristol Myers Squibb said it is partnering with Faro Health to use AI for clinical trial protocol design. The multiyear effort is intended to accelerate study design and drafting by converting narrative protocol elements—objectives, endpoints, and schedules—into structured digital assets that AI agents can then validate and optimize with traceability. BMS framed the initiative as part of a shift away from document-based workflows. Faro’s tooling is designed to ensure protocols align with industry frameworks such as the Tufts Center for the Study of Drug Development standards, and to simulate site and patient burden. The deal also positions Faro’s platform as a system of record across BMS’s development organization, signaling that protocol operations are increasingly becoming software-driven rather than text-driven.